Screening and surveillance for retinopathy of prematurity: A Wilson and Jungner framework approach

Athikarisamy, Sam Ebenezer; Lam, Geoffrey C.

doi:10.7189/jogh.13.03028

Cited by 3 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 Nevertheless, we should recognise that the advanced screening techniques and treatments on ROP are still unevenly distributed. [8][9][10][11] For instance, the major prevalent and YLD rates of blindness and vision loss were in developing regions and countries, while their higher increasing trends was observed in developed regions. These findings highlight that early diagnosis and timely treatments are urgently needed in the world.…”

Section: Discussionmentioning

confidence: 99%

Global, regional and national burden of retinopathy of prematurity among childhood and adolescent: a spatiotemporal analysis based on the Global Burden of Disease Study 2019

Wang,

Liu,

Zhang

et al. 2024

bmjpo

View full text Add to dashboard Cite

BackgroundThis study aimed to provide a comprehensive assessment of burden estimates and the secular trend of vision loss due to retinopathy of prematurity (ROP) among people younger than 20 years, at the global, regional and national levels.MethodsData were obtained from the Global Burden of Disease Study 2019 database. The average annual percentage change (AAPC) was calculated to quantify the temporal trends in the measures of vision loss.ResultsIn 2019, the global age-standardised rates (ASRs) of prevalence per 100 000 population was 86.4 for vision loss, specifically, 35 for moderate vision loss, 19.9 for severe vision loss, 31.6 for blindness due to ROP among people younger than 20 years. Moreover, the ASR of years lived with disability per 100 000 was 10.6 for vision loss, specifically, 1.1 for moderate vision loss, 3.6 for severe vision loss, 5.9 for blindness, respectively. From 1990 to 2019, the ASR of prevalence of blindness and vision loss due to ROP significantly increased, while its burden slightly decreased. Males showed higher ASR of prevalence than females in 2019, whereas females have larger increasing trend than males from 1990 to 2019. The global highest ASR of disease burden was observed in South Asia and Southern sub-Saharan Africa, as well as low sociodemographic index (SDI) regions in 2019.ConclusionsGlobally, although the burden decreased, the prevalence of childhood and adulthood vision loss due to ROP continues to increase. Reasonable resource allocation and advanced intervention are recommended to prevent and control the vision loss due to ROP.

show abstract

Section: Discussionmentioning

confidence: 99%

Global, regional and national burden of retinopathy of prematurity among childhood and adolescent: a spatiotemporal analysis based on the Global Burden of Disease Study 2019

Wang,

Liu,

Zhang

et al. 2024

bmjpo

View full text Add to dashboard Cite

show abstract

“…In In a study by Athikarisamy et al, they concluded that the primary benefit of routine screening is a significant increase in "lead time," which is the amount of time that passes between the time at which alterations become detectable and the period at which the disease would have manifested symptomatically if screening had not identified it. This is especially true for ROP since symptoms do show up in newborns or parents until the retina separates [24]. ROP screening coverage and quality improved after cooperative efforts on a national and international level.…”

Section: Screening Of Ropmentioning

confidence: 99%

A Narrative Review on Managing Retinopathy of Prematurity: Insights Into Pathogenesis, Screening, and Treatment Strategies

Bishnoi,

Prasad,

Upadhyay

et al. 2024

Cureus

View full text Add to dashboard Cite

Retinopathy of prematurity (ROP) is a rare proliferative ocular condition that can happen in premature babies (born preterm <36 weeks) or who weigh <1.5 kg at birth (low birth weight babies). ROP is a major cause of childhood blindness. It is a premature disease since retina vascularization is completed only by 40 weeks of life. The survivability for preterm infants has increased owing to recent improvements in neonatal care during the past decade. As a result, the prevalence of ROP has risen concurrently. The abnormal development of blood vessels in the retina is the cause of this illness.It occurs in two phases, phases 1 and 2. Most preterm infants weighing <1.5 kg need supplemental oxygen for respiratory support at birth. This leads to the initiation of phase 1 (vasoconstrictive phase). Phase 1 is characterized by loss of maternal-fetal connection and hyperoxia due to supplemental oxygen therapy. Oxygen's vasoconstrictive and obliterative action is primarily observed in developing retinal vessels. The inhibition of vascular endothelial growth factor follows from this. Phase 2 (vasoproliferative phase) shows the dilatation and tortuosity of the bigger existing vessels together with neovascularization and proliferation of new vessels into the vitreous when the baby is shifted from respiratory support to room air. Now, the retina gets hypoxic, where the retina becomes more metabolically active but is yet minimally vascularized, leading to VEGF-induced vasoproliferation, which might result in retinal detachment.Patients with ROP face the danger of loss of vision. If correct and quick treatment is not provided, they might land into permanent blindness. Yet, ROP remains one of the most preventable causes of childhood blindness worldwide. Blindness caused by ROP can only be avoided if screening programs are readily available, pertinent, and appropriate. The initial stage in the therapy of ROP is the screening of premature neonates. Timely screening and management for ROP is important to avoid this irreversible loss of vision. The treatment is based on the severity of the disease. Management may include pharmacological interventions like intravitreal and anti-vascular endothelial growth factor and nonpharmacological interventions like laser surgery, vitrectomy, and scleral buckling.We conducted a thorough literature search of studies on pathogenesis, risk factors, classification, and various treatment options for retinopathy of prematurity in infants, using a mixture of pertinent keywords. Only those studies published in peer-reviewed journals between 2010 and 2023 and written in English were included. Duplicate studies, unavailable in full-text for free, or studies unrelated to our subject matter were excluded. After thoroughly evaluating the selected studies, the results were synthesized and presented narratively. This article sheds light on the pathogenesis of ROP, particularly its relation to oxygen use, screening, and potential therapeutic management of ROP. Today advances in screening techniques have improved th...

show abstract

MDSCs promote pathological angiogenesis in ocular neovascular disease

Wu,

Zhong,

et al. 2024

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Screening and surveillance for retinopathy of prematurity: A Wilson and Jungner framework approach

Cited by 3 publications

References 26 publications

Global, regional and national burden of retinopathy of prematurity among childhood and adolescent: a spatiotemporal analysis based on the Global Burden of Disease Study 2019

Global, regional and national burden of retinopathy of prematurity among childhood and adolescent: a spatiotemporal analysis based on the Global Burden of Disease Study 2019

A Narrative Review on Managing Retinopathy of Prematurity: Insights Into Pathogenesis, Screening, and Treatment Strategies

MDSCs promote pathological angiogenesis in ocular neovascular disease

Contact Info

Product

Resources

About